{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T19:50:56Z","timestamp":1754164256788,"version":"3.41.2"},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>HU-014, a newly introduced botulinum toxin type A, has not been investigated for its efficacy and safety in crow's feet line (CFL) treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>Here, we compared the efficacy and safety of HU-014 and onabotulinumtoxinA in CFL treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>This was a randomized, double-blind, active drug\u2013controlled, multicenter, 16-week, Phase I\/III study designed to determine the noninferiority of HU-014 compared with onabotulinumtoxinA in moderate-to-severe CFL treatment. In the Phase III study, 290 subjects were randomized at a 1:1 ratio to receive a single treatment of HU-014 or onabotulinumtoxinA. The primary endpoint was the proportion of subjects achieving Grade 0 or 1 in the facial wrinkle scale on maximum smile at Week 4.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>The primary endpoint was achieved by 72% of the subjects with HU-014 and onabotulinumtoxinA treatments, supporting the noninferiority of HU-014 compared with onabotulinumtoxinA. All secondary efficacy outcomes were achieved by the subjects. The 2 groups showed no significant differences in the safety analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>HU-014 has noninferior efficacy and safety compared with onabotulinumtoxinA in the treatment of CFL.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000002807","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T21:03:50Z","timestamp":1617311030000},"page":"e127-e131","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Phase I\/III Clinical Trial to Evaluate the Safety and Efficacy of a New Botulinum Toxin (HU-014) Versus OnabotulinumtoxinA in Subjects With Moderate-to-Severe Crow's Feet Lines"],"prefix":"10.1097","volume":"47","author":[{"given":"Hye Sung","family":"Han","sequence":"first","affiliation":[{"name":"Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Ho","family":"Yoo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Su","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hun","family":"Huh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Seoul National University Bundang Hospital, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon-Hyo","family":"Kwon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang Won","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beom Joon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chung-Ang University College of Medicine, Seoul, Korea;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/DSS.0000000000001277","article-title":"Botulinum toxin in aesthetic medicine: myths and realities","volume":"44","author":"Dover","year":"2018","journal-title":"Dermatol Surg"},{"key":"R2-20250731","first-page":"1","article-title":"Efficacy and safety of neuronox((R)) for lateral canthal lines: a phase I\/III, multicenter, randomized, double-blind, active-controlled study","author":"Lim","year":"2019","journal-title":"J Dermatolog Treat"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/DSS.0000000000001512","article-title":"Impact of botulinum toxin type A treatment of the glabella and crow's feet on static forehead rhytides","volume":"45","author":"Ballard","year":"2019","journal-title":"Dermatol Surg"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/DSS.0000000000000128","article-title":"Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial","volume":"40","author":"Carruthers","year":"2014","journal-title":"Dermatol Surg"},{"key":"R5-20250731","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/DSS.0000000000000220","article-title":"Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial","volume":"41","author":"Moers-Carpi","year":"2015","journal-title":"Dermatol Surg"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1007\/s00266-017-0844-9","article-title":"OnabotulinumtoxinA (Botox) in the treatment of crow's feet lines in Japanese subjects","volume":"41","author":"Harii","year":"2017","journal-title":"Aesthet Plast Surg"},{"issue":"Suppl 3","key":"R7-20250731","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1111\/j.1524-4725.2010.01739.x","article-title":"Development and validation of a 6-point grading scale in patients undergoing correction of nasolabial folds with a collagen implant","volume":"36","author":"Monheit","year":"2010","journal-title":"Dermatol Surg"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF01578354","article-title":"Clinical use of Zyplast in correction of age- and disease-related contour deficiencies of the face","volume":"14","author":"Matti","year":"1990","journal-title":"Aesthet Plast Surg"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1067\/mjd.2002.124070","article-title":"Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet","volume":"47","author":"Lowe","year":"2002","journal-title":"J Am Acad Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002807","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:13:06Z","timestamp":1753999986000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000002807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000002807","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"type":"print","value":"1076-0512"},{"type":"electronic","value":"1524-4725"}],"subject":[],"published":{"date-parts":[[2020,10,15]]}}}